Frontlight ResearchEarly access
TerminatedPhase 1
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
Key facts
- Who runs it
- Baptist Health South Florida
- Where
- Miami, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 1 person enrolled
- Started
- 29 Jan 2024
- Ended
- 17 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
- Record updated
- 31 December 2025
- Why it stopped
- Slow enrollment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (49)Hide the full registry criteria
Who can take part
- Histologically confirmed HER-2 -positive breast cancer with newly-diagnosed brain metastases
- ECOG Performance Status (PS) of 0, 1, 2
- Patients with 1-10 brain metastases will be candidates for tucatinib, capecitabine, and trastuzumab with SRS at the discretion of the treating radiation oncologist. Intra-cranial brain metastasis must measure 3 cm or less in the greatest dimension
- Age 18 years or greater and being willing and able to sign a written informed consent. A signed informed consent must be obtained prior to any study specific procedures
- Life expectancy at least 12 weeks
- Any number of prior systemic therapies will be allowed, except tucatinib and capecitabine
- Hemoglobin ≥ 9g/dL, White blood count ≥3.0 × 10\^9/ L , Absolute Granulocyte count ≥1.5x 10\^9/ L and platelet count ≥100 × 10\^9/ L
- Serum bilirubin ≤ 1.5 × ULN
- AST and / or ALT <= 2 × ULN (≤ 5 × ULN when clearly attributable to the presence of liver metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance > 60mL/min
- Ability to comply with study procedures and monitoring
- For women of childbearing potential, a negative pregnancy test should be obtained within one week prior to the start of therapy
- Male or female patients of reproductive potential need to employ two highly effective and acceptable forms of contraception throughout their participation in the study and for 7 months after last dose of tucatinib, capecitabine and trastuzumab; Highly effective and acceptable forms of contraception are:
- Male condom plus spermicide
- Cap plus spermicide
- Diaphragm plus spermicide
- Copper T
- Progesterone T
- Levonorgestrel-releasing intrauterine system (e.g., Mirena®)
- Implants
- Hormone shot or injection
- Combined pill
- Mini-pill
- Patch; Postmenopausal woman on the study (that will not need contraception) is defined as:
- Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments
- LH and FSH levels in the postmenopausal range for women under 50
- Radiation-induced oophorectomy with last menses > 1 year ago
- Chemotherapy-induced menopause with >1 year interval since last menses
- Surgical sterilization (bilateral oophorectomy or hysterectomy); Men and women and members of all races and ethnic groups are eligible for this trial
Who cannot take part
- All toxicities from prior therapies must have resolved to CTCAE v 5.0 grade 1 or better by the time of study enrollment
- Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection, uncontrolled diabetes, second active malignancy) that could cause unacceptable safety risks or compromise compliance with the protocol
- Currently receiving other investigational cancer therapy within 4 weeks prior to start of study treatment with the exception of continuing therapy with GnRH analogues
- Concomitant use of strong cytochrome P450 (CYP)3A inhibitors including macrolide antibiotics (e.g., Telithromycin), antifungals (e.g., Itraconazole), antivirals (e.g., ritonavir), and Nefazodone
- Concomitant use of strong CYP2C8 inhibitor within 5 half-lives of the inhibitor
- Concomitant use of strong CYP3A4 inducers (e.g., phenytoin, rifampicin, carbamazepine, St. John's Wort) within 5 days prior to the first dose of study treatment
- Concomitant use of a strong CYP2C8 inducer within 5 days prior to the first dose of study treatment
- Evidence of intra-tumoral or peri-tumoral hemorrhage deemed significant by the treating physician
- Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom, e.g., Crohn's disease, malabsorption, or CTCAE grade >2 diarrhea of any etiology at baseline
- History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, New York Heart Association (NYHA) functional classification of 3 or 4
- Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C
- History of hypersensitivity to tucatinib, capecitabine, and trastuzumab, or any of its excipients
- Mean QT interval corrected heart rate (QTc) ≥ 470ms calculated from 3 electrocardiograms using Frediricia's Correction
- Left ventricular ejection fraction (LVEF) <50%
- Patients with leptomeningeal metastases documented by MRI or CSF evaluation
- Brain metastases within 5 mm of the optic chiasm or optic nerve
- Unable to undergo brain MRI
- History and/or confirmed corneal ulceration
- Pregnant or breast feeding
- Use of anthracyline will be prohibited on the protocol
Where in United States
- Miami Cancer Institute at Baptist Health, Inc.Miami, United States
About the trial
What the trial wants to find out
This research study will evaluate how well brain metastases associated with HER-2 positive breast cancer can be controlled using a type of radiation known as stereotactic radiosurgery (SRS) when combined with three therapeutic agents, tucatinib, capecitabine, and trastuzumab.
Read full original descriptionShow less
The combined use of SRS with the three drugs is considered investigational.
The group in the trial
- Investigational TreatmentTreatment being tested
Treatment: Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1 Trial of Tucatinib, Trastuzumab, and Capecitabine With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From HER-2 Positive Breast Cancer
- Publications
- Record updated
- 31 December 2025